Larimar Therapeutics Inc Stock

$3.45

2.07% yesterday

Nasdaq, Jul 14, 10:00 pm CET

ISIN

US5171251003

Symbol

LRMR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Overview Dividends Analysts Charts News Strategies

Larimar Therapeutics Inc Stock price

$3.45

-8.25 70.51% 5Y

Nasdaq, Closing price Mon, Jul 14 2025

+0.07 2.07%

ISIN

US5171251003

Symbol

LRMR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Key metrics

Basic

Market capitalization

$216.4m

Enterprise Value

$58.9m

Net debt

positive

Cash

$157.5m

Shares outstanding

64.0m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

1.5

Financial Health

Equity Ratio

85.8%

Return on Equity

-46.9%

ROCE

-71.2%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-105.0m | $-132.2m

EBIT

$-105.3m | $-137.4m

Net Income

$-95.2m | $-125.4m

Free Cash Flow

$-87.5m

EPS

$-1.5

FCF per Share

$-1.4

Short interest

18.4%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Larimar Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

18 Analysts have issued a Larimar Therapeutics Inc forecast:

17x Buy

94%

More details on Analyst Estimates Including Price Targets

18 Analysts have issued a Larimar Therapeutics Inc forecast:

Buy

94%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Larimar Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	18 18	25% 25% -
- Research and Development Expense	87 87	141% 141% -
EBITDA	-105 -105	108% 108% -
- Depreciation and Amortization	0.33 0.33	6% 6% -
EBIT (Operating Income) EBIT	-105 -105	107% 107% -
Net Profit	-95 -95	111% 111% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Larimar Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

6 days ago

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia

BALA CYNWYD, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the publication of two peer-reviewed articles highlighting nonclinical data on the therapeutic potential, pharmacology, and mechanism of action of nomlabofusp as a novel frataxi...

Neutral

GlobeNewsWire

●

21 days ago

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLA Written FDA recommendations for safety database include a total of at least 30 participants with continuous exposure for 6 months including a subset of at least 10 with 1-year; large majority of the exposure should be on the 50 mg dose BLA submission seeking accelerated ap...

Neutral

GlobeNewsWire

●

24 days ago

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss regulatory updates for the Company's nomlabofusp clinical development program for the treatment of Friedreich...

More Larimar Therapeutics Inc News

Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. It also focuses on using its intracellular platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania.

Head office	United States
CEO	Carole Ben-Maimon
Employees	65
Founded	2005
Website	larimartx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now